Raphael Koch

TL;DR: It is shown that lymphoma exosomes shield target cells from antibody attack and that exosome biogenesis is modulated by the lysosome-related organelle-associated ATP-binding cassette (ABC) transporter A3 (ABCA3), and mechanisms of cancer cell resistance to drugs and antibodies are linked in an ABCA3-dependent pathway of exosomal secretion.

TL;DR: It is demonstrated that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease.

TL;DR: Investigating dual effects in a TCL cohort from a phase 1, open-label study of duvelisib demonstrated promising clinical activity and an acceptable safety profile in relapsed/refractory TCL, as well as preclinical evidence of both tumor cell-autonomous and immune-mediated effects.

TL;DR: It demonstrated rapid induction of apoptosis and subsequent cell death broadly across hematologic cancer models in vitro, and MCL-1 depletion in a dose- and time-dependent manner was identified as a major mechanism through which AZD4573 induces cell death in tumor cells.

TL;DR: Analysis of the intrinsic drug efflux capacity of leukemic stem cells found the ABC transporter A3 (ABCA3) to be expressed consistently in acute myeloid leukemia (AML) samples and identified subcellular drug sequestration mediated by the genuinely intracellular ABCA3 as being a clinically relevant mechanism of intrinsic MDR.